152 related articles for article (PubMed ID: 26408679)
1. Targeting Topoisomerase II Activity in NSCLC with 9-Aminoacridine Derivatives.
Ferguson DM; Jacobson BA; Jay-Dixon J; Patel MR; Kratzke RA; Raza A
Anticancer Res; 2015 Oct; 35(10):5211-7. PubMed ID: 26408679
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of substituted 9-aminoacridine derivatives in small cell lung cancer.
Ryan E; Blake AJ; Benoit A; David MF; Robert AK
Invest New Drugs; 2013 Apr; 31(2):285-92. PubMed ID: 22821172
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of riccardin D on growth of human non-small cell lung cancer: in vitro and in vivo studies.
Xue X; Sun DF; Sun CC; Liu HP; Yue B; Zhao CR; Lou HX; Qu XJ
Lung Cancer; 2012 Jun; 76(3):300-8. PubMed ID: 22261315
[TBL] [Abstract][Full Text] [Related]
4. Novel acridine-based agents with topoisomerase II inhibitor activity suppress mesothelioma cell proliferation and induce apoptosis.
Raza A; Jacobson BA; Benoit A; Patel MR; Jay-Dixon J; Hiasa H; Ferguson DM; Kratzke RA
Invest New Drugs; 2012 Aug; 30(4):1443-8. PubMed ID: 21789510
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of DNA topoisomerases I and II and growth inhibition of HL-60 cells by novel acridine-based compounds.
Janočková J; Plšíková J; Kašpárková J; Brabec V; Jendželovský R; Mikeš J; Kovaľ J; Hamuľaková S; Fedoročko P; Kuča K; Kožurková M
Eur J Pharm Sci; 2015 Aug; 76():192-202. PubMed ID: 25960253
[TBL] [Abstract][Full Text] [Related]
6. Novel acridine-based compounds that exhibit an anti-pancreatic cancer activity are catalytic inhibitors of human topoisomerase II.
Oppegard LM; Ougolkov AV; Luchini DN; Schoon RA; Goodell JR; Kaur H; Billadeau DD; Ferguson DM; Hiasa H
Eur J Pharmacol; 2009 Jan; 602(2-3):223-9. PubMed ID: 19071108
[TBL] [Abstract][Full Text] [Related]
7. Search for human DNA topoisomerase II poisons in the group of 2,5-disubstituted-1,3,4-thiadiazoles.
Plech T; Kaproń B; Paneth A; Wujec M; Czarnomysy R; Bielawska A; Bielawski K; Trotsko N; Kuśmierz E; Paneth P
J Enzyme Inhib Med Chem; 2015 Dec; 30(6):1021-6. PubMed ID: 25792499
[TBL] [Abstract][Full Text] [Related]
8. Targeting topoisomerase II with trypthantrin derivatives: Discovery of 7-((2-(dimethylamino)ethyl)amino)indolo[2,1-b]quinazoline-6,12-dione as an antiproliferative agent and to treat cancer.
Catanzaro E; Betari N; Arencibia JM; Montanari S; Sissi C; De Simone A; Vassura I; Santini A; Andrisano V; Tumiatti V; De Vivo M; Krysko DV; Rocchi MBL; Fimognari C; Milelli A
Eur J Med Chem; 2020 Sep; 202():112504. PubMed ID: 32712536
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of benzo[a]phenazine derivatives as a dual inhibitor of topoisomerase I and II.
Zhuo ST; Li CY; Hu MH; Chen SB; Yao PF; Huang SL; Ou TM; Tan JH; An LK; Li D; Gu LQ; Huang ZS
Org Biomol Chem; 2013 Jun; 11(24):3989-4005. PubMed ID: 23657605
[TBL] [Abstract][Full Text] [Related]
10. Anti-proliferative effects of simocyclinone D8 (SD8), a novel catalytic inhibitor of topoisomerase II.
Sadiq AA; Patel MR; Jacobson BA; Escobedo M; Ellis K; Oppegard LM; Hiasa H; Kratzke RA
Invest New Drugs; 2010 Feb; 28(1):20-5. PubMed ID: 19132295
[TBL] [Abstract][Full Text] [Related]
11. Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines.
Kasahara K; Fujiwara Y; Sugimoto Y; Nishio K; Tamura T; Matsuda T; Saijo N
J Natl Cancer Inst; 1992 Jan; 84(2):113-8. PubMed ID: 1310509
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 1,2-diphenylethene derivatives as human DNA topoisomerase II catalytic inhibitors and antitumor agents.
Xu G; Li Z; Ding Y; Shen Y
Eur J Med Chem; 2022 Dec; 243():114706. PubMed ID: 36063665
[TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis, Dynamic Docking, Biochemical Characterization, and
Arencibia JM; Brindani N; Franco-Ulloa S; Nigro M; Kuriappan JA; Ottonello G; Bertozzi SM; Summa M; Girotto S; Bertorelli R; Armirotti A; De Vivo M
J Med Chem; 2020 Apr; 63(7):3508-3521. PubMed ID: 32196342
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore Hybridization To Discover Novel Topoisomerase II Poisons with Promising Antiproliferative Activity.
Ortega JA; Riccardi L; Minniti E; Borgogno M; Arencibia JM; Greco ML; Minarini A; Sissi C; De Vivo M
J Med Chem; 2018 Feb; 61(3):1375-1379. PubMed ID: 29077404
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[a]phenazin derivatives as dual topoisomerase I/II inhibitors.
Yao BL; Mai YW; Chen SB; Xie HT; Yao PF; Ou TM; Tan JH; Wang HG; Li D; Huang SL; Gu LQ; Huang ZS
Eur J Med Chem; 2015 Mar; 92():540-53. PubMed ID: 25599951
[TBL] [Abstract][Full Text] [Related]
16. QS-ZYX-1-61 induces apoptosis through topoisomerase II in human non-small-cell lung cancer A549 cells.
Chen MC; Pan SL; Shi Q; Xiao Z; Lee KH; Li TK; Teng CM
Cancer Sci; 2012 Jan; 103(1):80-7. PubMed ID: 21920000
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and antiproliferative activity of 9-benzylamino-6-chloro-2-methoxy-acridine derivatives as potent DNA-binding ligands and topoisomerase II inhibitors.
Zhang W; Zhang B; Zhang W; Yang T; Wang N; Gao C; Tan C; Liu H; Jiang Y
Eur J Med Chem; 2016 Jun; 116():59-70. PubMed ID: 27060757
[TBL] [Abstract][Full Text] [Related]
18. EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors.
Fillmore CM; Xu C; Desai PT; Berry JM; Rowbotham SP; Lin YJ; Zhang H; Marquez VE; Hammerman PS; Wong KK; Kim CF
Nature; 2015 Apr; 520(7546):239-42. PubMed ID: 25629630
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, cytotoxicity and topoisomerase II inhibitory activity of lomefloxacin derivatives.
Zhou Y; Xu X; Sun Y; Wang H; Sun H; You Q
Bioorg Med Chem Lett; 2013 May; 23(10):2974-8. PubMed ID: 23566520
[TBL] [Abstract][Full Text] [Related]
20. A new 1-nitro-9-aminoacridine derivative targeting yeast topoisomerase II able to overcome fluconazole-resistance.
Rząd K; Paluszkiewicz E; Gabriel I
Bioorg Med Chem Lett; 2021 Mar; 35():127815. PubMed ID: 33486051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
